Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imvotamab - IGM Biosciences

Next Previous
X
Search
Drug Profile

Imvotamab - IGM Biosciences

Alternative Names: CD20 x CD3 bispecific antibody; IGM 2323

Latest Information Update: 07 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IGM Biosciences
  • Class Antineoplastics; Antirheumatics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Myositis; Rheumatoid arthritis; Systemic lupus erythematosus
  • Preclinical Autoimmune disorders

Most Recent Events

  • 29 Jul 2024 Phase-I clinical trials in Myositis in USA (IV) (NCT06524687)
  • 24 Jul 2024 IGM Biosciences terminates a phase I/II trial in Non-Hodgkin's lymphoma (Recurrent, Second-line therapy or greater) in Italy, Czech Repbulic, USA, Australia, Spain and France (IV) to prioritize clinical development of imvotamab (NCT04082936)
  • 10 May 2024 Phase-I clinical trials in Rheumatoid arthritis (Treatment-experienced) in Poland (IV) (NCT06087406)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top